QPPV.COM KNOWLEDGE ASSESSMENT

Xeligekimab: Classification, Mechanism, Clinical Evidence and Pharmacovigilance

Test your understanding of the concepts covered by Xeligekimab: Classification, Mechanism, Clinical Evidence and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 A patient reports a new rash during treatment. Which case-review approach best supports differential diagnosis?

Describe whether it is the target plaque disease, a new eruption, infection or suspected hypersensitivity Code every rash as worsening psoriasis because that is the authorised indication Classify it as hypersensitivity solely because it occurred after a dose Record only that a rash occurred, since further clinical detail does not affect assessment

Question 2 of 10 Which description most accurately characterises xeligekimab’s molecular target and action?

A fully human IgG4 antibody that binds IL-17A and reduces its interaction with receptor complexes A fully human antibody that binds IL-17RA and prevents all cytokine signalling through that receptor A small molecule that inhibits production of IL-17A by immune cells A conjugated antibody that delivers a cytotoxic agent to IL-17A-producing cells

Question 3 of 10 Why does the IL-23/Th17/IL-17 pathway provide a therapeutic rationale for xeligekimab in plaque psoriasis without establishing efficacy for every immune-mediated disease?

A biologically relevant pathway supports a hypothesis, but clinical evidence and authorisation remain indication-specific A shared inflammatory pathway means efficacy can be assumed across all immune-mediated conditions A cytokine-targeting mechanism establishes comparative superiority over other biologics A plausible mechanism removes the need to evaluate the treated population in clinical studies

Question 4 of 10 A patient’s psoriasis worsens after several missed doses. What is the most appropriate interpretation for an effectiveness case?

Assess adherence and exposure because relapse after missed doses may not represent pharmacologic failure Classify the case as confirmed lack of efficacy because disease worsened during treatment Exclude the case from review because missed doses make all effectiveness information irrelevant Conclude that the authorised mechanism has failed in this patient without further assessment

Question 5 of 10 What additional considerations are important when interpreting longer-term follow-up or phase 2 evidence?

Dose, sample size, attrition, rescue treatment and endpoint timing Whether the findings can be treated as a direct comparison with every marketed biologic Whether early response rates can replace assessment of treatment persistence Whether spontaneous reports can be added to trial participants to increase the denominator

Question 6 of 10 Which set of information best supports assessment of a suspected lack-of-efficacy report?

Assessment tool, baseline and follow-up scores, body sites, adherence, treatment duration and dose changes Only the reporter’s conclusion that the medicine did not work Only the date of first dose and the patient’s prior diagnosis Only the adverse events reported during the same treatment period

Question 7 of 10 What is the most defensible conclusion from the phase 3 PASI results?

They show substantial short-term responses in the studied Chinese population under the trial conditions They establish that every treated patient will maintain response after stopping treatment They prove safety and efficacy in populations not represented in the trial They show that the same response rates will occur with any dose or treatment regimen

Question 8 of 10 Which information is most useful when evaluating reported inflammatory bowel symptoms during treatment?

Onset, prior inflammatory bowel disease, investigations and clinical course Only the most recent PASI score Only whether the patient received phototherapy before xeligekimab A definitive drug-causality conclusion before collecting clinical details

Question 9 of 10 What is the most appropriate approach when reviewing aggregate safety data from trials, observational cohorts and spontaneous reports?

Keep sources and denominators distinct, and do not combine small uncontrolled cohorts with spontaneous reports to create a comparative rate Pool all reported events and divide by trial participants to estimate a comparative incidence Use event counts alone because exposure and follow-up are not needed for aggregate review Treat spontaneous-report counts as directly comparable with controlled-trial rates

Question 10 of 10 Which topics are specifically relevant to aggregate monitoring for xeligekimab?

Infections, hypersensitivity, gastrointestinal inflammatory events, immunogenicity, treatment persistence and effectiveness Only infections, because other events cannot be evaluated for a cytokine-neutralising antibody Only psoriasis response, because safety is assessed exclusively at the individual-case level Only hypersensitivity and immunogenicity, excluding treatment persistence and effectiveness

QPPV.com

Xeligekimab: Classification, Mechanism, Clinical Evidence and Pharmacovigilance

Cookie Settings